Any feedback?
Literature summary extracted from
- Cancer procoagulant (1994), Methods Enzymol., 244, 568-583.
Activating Compound
| EC Number | Activating Compound | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.4.22.26 | additional information | no activation with 0.005 mM cysteine and 4 mM KCN | Homo sapiens | |
| 3.4.22.26 | additional information | no activation with 0.005 mM cysteine and 4 mM KCN | Rattus norvegicus |
General Stability
| EC Number | General Stability | Organism |
|---|---|---|
| 3.4.22.26 | Polyethylene glycol preparation yields stable enzyme | Homo sapiens |
| 3.4.22.26 | Polyethylene glycol preparation yields stable enzyme | Rattus norvegicus |
| 3.4.22.26 | Prefers lipid environment, phospholipids stabilize | Homo sapiens |
| 3.4.22.26 | Prefers lipid environment, phospholipids stabilize | Rattus norvegicus |
| 3.4.22.26 | Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum | Homo sapiens |
| 3.4.22.26 | Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum | Rattus norvegicus |
Inhibitors
| EC Number | Inhibitors | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.4.22.26 | alpha1-Aantichymotrypsin | weak | Homo sapiens | |
| 3.4.22.26 | alpha1-Aantichymotrypsin | weak | Rattus norvegicus | |
| 3.4.22.26 | alpha2-Macroglobulin | weak | Homo sapiens | |
| 3.4.22.26 | alpha2-Macroglobulin | weak | Rattus norvegicus | |
| 3.4.22.26 | antipain | enhanced in reduced environment | Homo sapiens |  |
| 3.4.22.26 | antipain | enhanced in reduced environment | Rattus norvegicus | |
| 3.4.22.26 | diisopropylfluorophosphate | strong | Homo sapiens | |
| 3.4.22.26 | diisopropylfluorophosphate | strong | Rattus norvegicus | |
| 3.4.22.26 | HgCl2 | strong, less effective in reduced environment | Homo sapiens | |
| 3.4.22.26 | HgCl2 | strong, less effective in reduced environment | Rattus norvegicus | |
| 3.4.22.26 | iodoacetamide | strong, still enhanced in reduced environment | Homo sapiens | |
| 3.4.22.26 | iodoacetamide | strong, still enhanced in reduced environment | Rattus norvegicus | |
| 3.4.22.26 | leupeptin | enhanced in reduced environment | Homo sapiens | |
| 3.4.22.26 | leupeptin | enhanced in reduced environment | Rattus norvegicus | |
| 3.4.22.26 | additional information | cystatin, alpha1-antiprotease, antithrombin III | Homo sapiens | |
| 3.4.22.26 | additional information | cystatin, alpha1-antiprotease, antithrombin III | Rattus norvegicus | |
| 3.4.22.26 | Peptidyl chloromethanes | - |
Homo sapiens | |
| 3.4.22.26 | Peptidyl chloromethanes | - |
Rattus norvegicus | |
| 3.4.22.26 | Peptidyl diazomethanes | - |
Homo sapiens | |
| 3.4.22.26 | Peptidyl diazomethanes | - |
Rattus norvegicus | |
| 3.4.22.26 | Peptidyl dimethylsulfonium salts | - |
Homo sapiens | |
| 3.4.22.26 | Peptidyl dimethylsulfonium salts | - |
Rattus norvegicus | |
| 3.4.22.26 | phenylmethylsulfonyl fluoride | - |
Homo sapiens | |
| 3.4.22.26 | phenylmethylsulfonyl fluoride | - |
Rattus norvegicus | |
| 3.4.22.26 | trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane | enhanced in reduced environment | Homo sapiens | |
| 3.4.22.26 | trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane | enhanced in reduced environment | Rattus norvegicus | |
Metals/Ions
| EC Number | Metals/Ions | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.4.22.26 | Ca2+ | requirement, 7 mM | Homo sapiens | |
| 3.4.22.26 | Ca2+ | requirement, 7 mM | Rattus norvegicus | |
| 3.4.22.26 | Mg2+ | 10 mM | Homo sapiens | |
| 3.4.22.26 | Mg2+ | 10 mM | Rattus norvegicus | |
| 3.4.22.26 | Mg2+ | requirement, can replace Ca2+ | Homo sapiens | |
| 3.4.22.26 | Mg2+ | requirement, can replace Ca2+ | Rattus norvegicus | |
| 3.4.22.26 | Mn2+ | requirement, can replace Ca2+ | Homo sapiens | |
| 3.4.22.26 | Mn2+ | requirement, can replace Ca2+ | Rattus norvegicus | |
| 3.4.22.26 | Mn2+ | but different binding site than Ca2+ (or Mg2+), 0.02 mM | Homo sapiens | |
| 3.4.22.26 | Mn2+ | but different binding site than Ca2+ (or Mg2+), 0.02 mM | Rattus norvegicus | |
| 3.4.22.26 | additional information | binding cancer procoagulant to a surface changes its divalent ion requirements | Homo sapiens | |
| 3.4.22.26 | additional information | binding cancer procoagulant to a surface changes its divalent ion requirements | Rattus norvegicus |
Molecular Weight [Da]
| EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
|---|---|---|---|---|
| 3.4.22.26 | additional information | - |
- |
Rattus norvegicus |
| 3.4.22.26 | additional information | - |
amino acid composition of rabbit V2 and human amnion-chorion enzymes | Homo sapiens |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.22.26 | Homo sapiens | - |
- |
- |
| 3.4.22.26 | Rattus norvegicus | - |
- |
- |
Oxidation Stability
| EC Number | Oxidation Stability | Organism |
|---|---|---|
| 3.4.22.26 | sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize | Homo sapiens |
| 3.4.22.26 | sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize | Rattus norvegicus |
Posttranslational Modification
| EC Number | Posttranslational Modification | Comment | Organism |
|---|---|---|---|
| 3.4.22.26 | no glycoprotein | no glycoprotein | Homo sapiens |
| 3.4.22.26 | no glycoprotein | no glycoprotein | Rattus norvegicus |
Source Tissue
| EC Number | Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|---|
| 3.4.22.26 | amelanotic melanoma cell | - |
Rattus norvegicus | - |
| 3.4.22.26 | carcinoma cell | - |
Rattus norvegicus | - |
| 3.4.22.26 | Lewis lung carcinoma cell | - |
Rattus norvegicus | - |
| 3.4.22.26 | additional information | unique in tumor | Homo sapiens | - |
| 3.4.22.26 | additional information | unique in tumor | Rattus norvegicus | - |
| 3.4.22.26 | additional information | unique in fetal tissues, not in normally differentiated tissues | Homo sapiens | - |
| 3.4.22.26 | additional information | unique in fetal tissues, not in normally differentiated tissues | Rattus norvegicus | - |
| 3.4.22.26 | placenta | amnion-chorion tissue | Homo sapiens | - |
| 3.4.22.26 | Walker carcinoma 256 cell | - |
Rattus norvegicus | - |
Substrates and Products (Substrate)
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.22.26 | Factor X + H2O | primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19 | Homo sapiens | Factor Xa + ? | - |
? | |
| 3.4.22.26 | Factor X + H2O | primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19 | Rattus norvegicus | Factor Xa + ? | - |
? | |
Temperature Optimum [°C]
| EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|---|
| 3.4.22.26 | 37 | - |
assay at | Homo sapiens |
| 3.4.22.26 | 37 | - |
assay at | Rattus norvegicus |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
